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ABSTRACT
ANN KELLY PATRICK: Approaches Towards the Synthesis of Ketamine Metabolites
(Under the direction of Dr. John Rimoldi)
Major Depressive disorder (MDD) plagues society and stands at the forefront of
research as MDD affects approximately 16% of the population. Pharmaceutical drugs
including the selective serotonin reuptake inhibitors (SSRIs) have been used for MDD
treatment and remain a popular option today. However, current antidepressant treatments
have proven to be ineffective in just less than half of the patients. Research continues with
the goal to better understand the mechanisms of the pathology of depression and to search
for other treatment options. For example, the stress-neurogenesis hypothesis investigates
the role of stress and decreased neuroplasticity within MDD.
Supporting the stress-neurogenesis hypothesis, the well-known anesthesia drug,
ketamine, has shown antidepressant effects linked to glutamate neurotransmission and the
successive downstream effects. However, the positive effects sustain after the rapid hepatic
metabolism of ketamine leading scientists to explore key metabolites of ketamine and their
effects on depressive symptoms.
One of the ketamine metabolites, (2R, 6R)-hydroxynorketamine (HNK), has shown
clinical benefits while decreasing the adverse side effects of ketamine in treatment-resistant
MDD. The aim of this thesis research is to explore a simple oxidation protocol for the direct
synthesis of hydroxynorketamine from the precursor compound norketamine.
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INTRODUCTION

Overview of MDD
Major Depressive disorder, commonly known as depression, affects more than 12%
of men and 20% of women in the United States and more than 264 million people
worldwide. MDD is characterized by significant mood changes associated with extreme
sadness or irritability that lasts for longer than two weeks and is followed by
psychophysiological changes such as alterations in eating, sleeping patterns, concentration,
socialization, and sexual desires that can be accompanied by suicidal thoughts. Within the
etiology of MDD lies ambiguity as depression correlates with both environmental and
genetic factors. Genetic contribution was tested utilizing a twin study and revealed a 37%
heritability; however, no one gene has been linked to MDD.1 With a lifetime prevalence of
16%, depression stands with the highest prevalence of all mood disorders and the second
most common mental illness.2 Physician office medical records document depression for
9.3% of all patients.3 According to the World Health Organization, approximately 800,000
people die each year due to suicide.4 Treatment of depression typically involves
pharmacotherapy, psychotherapy, or supportive measures. With depression's high
morbidity rates, MDD has significant economic and personal importance within society,
guiding immense research efforts to improve the treatment of MDD.
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History of Neuropathology, Theories, and Treatment of MDD
The dominant theory throughout the history of MDD remains the monoaminedeficiency hypothesis. The monoamine-deficiency hypothesis targets the norepinephrine
and serotonin systems as the basis for depression. Within this hypothesis, the current FDA
approved treatments include MAO-Is, TCAs, and SSRIs. These drugs function to increase
the concentration of norepinephrine or serotonin at the synaptic cleft.5 However, these
treatments display unimpressive efficacy and therapeutic delays of 2 to 4 weeks. One-third
to half of the population is reported to not respond to treatment for MDD, and consequently,
this subset of the population is currently left without treatment.1-2 The prevalence of
treatment-resistant depression alongside incomplete data concerning the monoamine
hypothesis led to explorations of novel molecular pathways. The latency of clinical benefits
directed most researchers to conclude that MDD is not a result of the direct impact of
monoaminergic neurotransmitters such as norepinephrine and serotonin, but instead
consists of downstream effects.

The Stress Neurogenic Theory
A recent theory concerning the neuropathology of MDD is the stress-neurogenesis
hypothesis. This theory involves stress and growth factors within the hypothalamicpituitary-adrenal (HPA) axis. Stress is processed in the cerebral cortex and relayed in the
hypothalamus, causing a release of corticotropin-releasing hormone (CRH) onto anterior
pituitary receptors that in response secrete adrenocorticotropic hormone (ACTH) that
signal the adrenal cortex to release cortisol into the blood. The increase in cortisol signals
the hypothalamus to decrease CRH production as a feedback inhibition to maintain
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homeostasis. Increased levels of cortisol in the blood and CRH in the cerebral spinal fluid
have been reported in individuals with MDD, and disruptions within the feedback
inhibition of the HPA axis have been shown in severely depressed individuals. Moreover,
an increase in cortisol is linked to a decrease in Brain-Derived Neurotropic Factor (BDNF).
BDNF is a neurotrophic peptide that is essential for axonal growth, neuronal survival, and
synaptic plasticity. The decrease in BDNF, ultimately caused by stress, stunts neurogenesis
in the hippocampus, amygdala, and prefrontal cortex, causing atrophy of these critical
limbic structures. The degradation of the critical limbic structures could be accountable for
the symptomology of MDD. BDNF appears as a prominent link to MDD as decreased
BDNF levels have been found in patients who committed suicide, and increased levels of
BDNF have resulted from current antidepressant drugs and electroconvulsive therapies.1-2
With the alternate theory of the stress-neurogenesis hypothesis, the major
excitatory neurotransmitter, glutamate, has been postulated as an option to offset the
neuronal loss. The glutamatergic system induces neuroplasticity with the building of
synapses to aid in learning and the retrieval of memories.5

Ketamine, Its Metabolites, and Potential Antidepressant Use
Ketamine, a short-acting anesthesia drug, acts as a glutamatergic agent and shows
promise in the area of MDD treatment. The drug is commonly used for general anesthesia,
especially in pediatric anesthesia cases. At sub-anesthesia doses, the drug generates pain
relief, classifying the drug as an analgesic. At high doses, users report out of body
experiences sometimes coupled with delirium and symptoms of psychosis. The drug is a
noncompetitive N-methyl-D-aspartate (NMDA) glutamate receptor antagonist causing
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interferences within the glutamatergic system. The drug affects other receptors such as
muscarinic, nicotinic, cholinergic, and opioid receptors. A variety of downstream effects
commonly associated with antidepressant effects have been reported, including increases
in BDNF and mTOR protein levels, a mammalian kinase encoded by the mTOR gene that
is the mammalian target of rapamycin. The research proposes that the excitatory
neurotransmitter glutamate increases within the synaptic slept due to increased glutamate
release and AMPA receptor expression. The increase of glutamate provokes an increase in
BDNF and mTOR, triggering extended synaptic growth. The drug shows anti-depressive
benefits within two hours, and the effects can continue for a week.6 The R enantiomer is
shown to be the source of the sustained antidepressant effects.7 The proposed signaling
cascade links ketamine to antidepressant effects via the stress-neurogenesis hypothesis.
However, ketamine's high abuse liability and psychotomimetic (psychotogenic) effects
limit its clinical benefits as an antidepressant for everyday use.6 When researchers
examined patients reporting anti-depressive effects of ketamine, they found low
concentrations of ketamine and higher concentrations of its metabolites.8
Cl

OH

O
Cl

NHMe

O
Cl

O

NH2
NH2

Ketamine (1)

Norketamine (2)

(2R,6R)-Hydroxynorketamine (3)

Figure I: Molecular structures of ketamine, norketamine, and (2R,6R)hydroxynorketamine
The major metabolites of ketamine are depicted in Figure I. Exploring metabolites
of ketamine led to promising pharmacotherapies as various metabolites show the same
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benefits with ketamine, yet without many of the negative effects. The N-demethylation of
ketamine yields norketamine (2), which is thereafter hydroxylated to produce multiple
hydroxynorketamines. Particularly, the stereoisomer, (2R,6R)-hydroxynorketamine
[(2R,6R)-HNK: 3], has shown improved clinical efficacy alongside increased therapeutic
windows in multiple animal behavioral tests. The metabolite (2R,6R)-HNK reduces
psychotic effects compared to the parent drug, lowering the abuse liability.9 Lumsden
associates ketamine’s abuse liability and adverse behavioral effects to NMDAR inhibition.
The metabolite (2R,6R)-HNK functions differently than ketamine as it does not bind nor
inhibit NMDA receptors at antidepressant-relevant concentrations (10 "L).10 Also,
(2R,6R)-HNK did not inhibit !-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) receptors. Lumsden reported that dissociation effects were experienced with 30
mg/kg doses of ketamine, while doses of up to 375 mg/kg of (2R,6R)-HNK showed no
effect. Also, he reported that unlike ketamine, mice did not self-administer (2R,6R)-HNK
at anti-depressant doses.10 The exact mechanisms of (2R,6R)-HNK are unknown, but
Fukumoto connected the antidepressant effects to the activity-dependent release of BDNF
and mTOR signaling that is mediated by the stimulation of voltage dependent calcium
channels.11 The release of BDNF and mTOR signaling increased synaptogenesis and
synaptic function in the medial prefrontal cortex. Zanos revealed group II metabotropic
glutamate receptor subtype 2 (mGlu2) inhibition via (2R, 6R)-HNK to enhance cortical
quantitative EEG (qEEG) power in mice, a relevant marker to test antidepressant-relevant
actions.9 The increased AMPA activation, BDNF activity, mGlu2 receptor inhibition, and
resulting downstream pathways, including mTOR, are thought to be the source of
synaptogenesis, generating the antidepressant effects of (2R,6R)-HNK. Moreover, not
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being processed in the liver, (2R,6R)-HNK avoids many drug interactions. The metabolite
(2R,6R)-HNK provides a plausible drug of choice to study with promising data in the
ongoing search for better treatment of MDD, specifically with treatment-resistant
depression. Due to the increased interest surrounding (2R,6R)-HNK, the objective of this
thesis research was to explore a novel route for the synthesis of (2R,6R)-HNK to improve
overall reaction yields and to reduce cost and number of synthetic steps.
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RESULTS AND DISCUSSION

With the promise of progress in antidepressant pharmacotherapy, novel approaches
for the synthesis of (2R,6R)-HNK (3) were considered based on prior synthesis. Two
chemical syntheses of compound 3 have been reported to date. The first synthesis was
reported by Morris et. al in 2017 and relied on a modification of an original route for
ketamine synthesis (Figure II).12 Commercially available ketone 4 was converted in a 5step sequence to enantiopure R-norketamine (5) through initial bromination of the ketone,
subsequent condensation with ammonium hydroxide, and a thermal rearrangement to
afford racemic norketamine in 44% overall yield. Chiral resolution using pyroglutamic acid
provided 5 in gram scale, which was subjected to a Rubottom oxidation to install the αketo-alcohol with the desired stereochemistry and an excellent diastereoselective ratio. A
series of amine protection/deprotection protocols were also included in the synthesis.
OH
Cl

O

Cl

5-steps

O

Cl

NH2

4

5-steps

5

O

NH2

3

Figure II: Morris synthesis of (2R,6R)-HNK (3)

In 2017, the Corey group reported an alternate synthesis of 3 employing as a key step the
enantioselective epoxidation of 1-ortho-chlorophenylcyclohexene 6 using a modified
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Jacobsen’s salen-type catalyst (catalyst B, Figure III) and NaOCl as oxidant.13
Regioselective ring opening of the epoxide with titanium isopropoxide and
trimethylsilylazide followed by a Dess−Martin periodinane oxidation afforded enantiopure
7 which was reduced to the corresponding amine and converted to 3 utilizing a Rubottom
oxidation and similar reaction sequences as first reported by Morris.

OH
Cl

Cl

3-steps
6

O
Cl

6-steps

N3

7

O

NH2

3

Figure III: Corey’s synthesis of (2R,6R)-HNK (3)

Each reported synthesis relies on a late-stage Rubottom oxidation of key intermediate
norketamine (2), with this oxidation method requiring the use of an alkylithium, low
reaction temperatures, peroxybenzoic acid and a fluoride source. Our approach was to
synthesize sufficient quantities of racemic norketamine and to use this intermediate to
explore an inexpensive oxidation protocol for the synthesis of hydroxynorketamine
metabolites, namely, the α-hydroxylation reaction of ketones with dimethyl sulfoxide
catalyzed by iodine or N-bromosuccinimide.
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Synthetic Approach and Specific Aims
The specific aims of this thesis research project are:
1) To synthesize sufficient quantities of norketamine (2) using established procedures.
2) To explore the potential utility of the I2- or NBS-catalyzed α-hydroxylation reaction of
norketamine with dimethylsulfoxide (DMSO).14

This oxidation protocol is attractive insofar as DMSO acts as an oxidant, oxygen source,
and solvent. Moreover, the reaction conditions are mild and reagents are inexpensive, in
comparison the Rubottom oxidation protocol. This sequence would provide direct access
to hydroxylated norketamine analogs (stereochemistry notwithstanding).
OH
Cl

O

amine protection
NH2

Cl

O

DMSO
I2 or NBS

HN

Cl

O

HN
O-R

O-R
O

Norketamine (2)

O

Figure IV: Proposed scheme for the synthesis of hydroxynorketamine
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Specific Aim 1: 3-Step Synthesis of Norketamine (2)

Step 1 (Palladium Catalyzed Arylation Reaction): We initiated the synthesis by using a
palladium-catalyzed ketone arylation reaction between 1-bromo-2-chlorobenene (8) and
cyclcohexanone (9) to afford the desired product, 2-(2-chlorophenyl)cyclohexan-1-one
(10; Scheme 1). This specific reaction was reported by Willis in 2004 as an adaptation of
the Buchwald arylation reaction and represents an efficient method for the creation of
alpha-arylated ketones.15 The reaction was performed in toluene at 80 oC using 0.5 mol %
of Pd2-(dba)3, 1.2 mol % of Xantphos, and Cs2CO3 affording product 10 in 51% yield
(unoptimized). The spectroscopic data (1H NMR,
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C NMR, MS) matched the literature

reported values and the product yields were consistent when repeated reactions were
performed.

O

Cl

Pd2(dba3);
Xantphos
CsCO3; Toulene
(51%)

Br

+
8

Cl

O

Xantphos

10

9

Pd2(dba)3

Scheme 1: Synthesis of 2-(2-chlorophenyl)-cyclohexan-1-one (10)

Step 2 (Aliphatic Nitration Reaction): In 2017, Zhang et al reported a 4-step synthesis of
ketamine (1), employing as a key step, a copper-assisted direct nitration of aryl and alkyl
substituted cyclic ketones with ceric ammonium nitrate [(NH4)2Ce(NO3)6: CAN] (Scheme
2).16 In this reaction prototype, it was speculated that CAN serves three important
10

functions: as a Lewis acid (promoting enolization of ketone starting material), an oxidant,
and a nitrating reagent. Although the role of copper had not been fully elucidated for this
reaction, it is believed to stabilize an intermediate radical species. This reaction was
conducted using the reported reaction conditions (conventional heating in oil bath) in
addition to performing the reaction using an alternative method of heating, microwave
irradiation.

Cl

Cu(OAc)2
(NH4)2Ce(NO3)6
DCE, 80 °C

O

Cl

O

NO2

heat 12-96 h (NR)
microwave 50 min (22%)
11

10

Scheme 2: Synthesis of 2-(2-chlorophenyl)-2-nitrocyclohexan-1-one (11)

We utilized identical experimental conditions for the nitration reaction using the
conventional heating method as reported by Zhang, who optimized reaction conditions for
the synthesis of nitrated products from a small library of alpha-substituted cyclic ketone
precursors. It is important to note Zhang’s reported yields of nitrated products (using 14
different substrates) were modest and varied with an average yield of approximately 55%.
The reaction conditions for the synthesis of 11 used 1, 2-dichloroethane (DCE) as a solvent
with the addition of 10, Cu(OAc)2 and (NH4)2Ce(NO3)6 in a sealed tube under an argon
atmosphere and heating in an oil bath at 80 oC. When the reaction was repeated using these
conditions, the desired product of the reaction, 2-(2-chlorophenyl)-2-nitrocyclohexan-1one (11) was not observed, even after repeated attempts, prolonged reaction times (up to 4
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days), and higher reaction temperatures (100 oC). Alternate commercial sources of CAN
were also used in separate reactions to rule out reagent quality issues, but without success.
It is not clear why the nitration reaction failed in our hands when conducted using identical
reaction conditions as reported in the literature. Notwithstanding, the literature yield for
the conversion of 10 to 11 was reported to be 51% after product purification by silica gel
column chromatography. We then turned our efforts to using microwave irradiation rather
than conventional heating to provide some insight. We utilized a Biotage Initiator
Microwave Synthesizer (2.45 GHz) and performed the nitration reaction using similar
reaction conditions reported under conventional heating. Since microwave irradiation
allows reaction times to exponentially decrease, we anticipated 10-20 minutes of
microwave heating would suffice. Using DCE as a solvent was appropriate for conducting
the microwave heating (The heating performance of a solvent under microwave irradiation
is dependent on its ability to convert electromagnetic energy into heat and is related to the
solvent dielectric constant). In initial experiments, microwave irradiation was applied to
the reaction mixture in 10-minute intervals with reaction monitoring and required 50
minutes of microwave heating at 80 °C. Each 10-minute interval was preceded with prestirring (2 min) due to a concern with inconsistency of stirring throughout the microwave
irradiation timeframe, based on visual inspection of the reaction mixture. Although not
fully optimized, reactions performed under these conditions afforded the nitration product
11, albeit in low yields (average yield 22%).
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Step 3 (Nitro Reduction)
Cl

O

Zn powder
AcOH
NO2

Cl

O

12 h (69%)

NH2

2

11

Scheme 3: Synthesis of 2-(2-chlorophenyl)-2-aminocyclohexan-1-one (norketamine; 2)

This final step involved the reduction of the nitro group to an amine group with zinc powder
and the weak acid solvent acetic acid (Scheme 3). This resulted in a 69% product yield
(isolated as free base), and the spectroscopic data matched the literature reported values for
norketamine. Around the time the three-step synthesis of norketamine was completed, a
commercial vendor (Advanced ChemBlocks Inc.) began to offer this rare compound in
gram quantities at a reasonable price, and one gram was purchased in order to explore the
novel oxidation reaction.
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Specific Aim 2: Exploring the potential of the DMSO oxidation of norketamine
In order to evaluate the potential of applying the DMSO oxidation to the substrate
norketamine, initial amine group protection was warranted. Treatment of 2 with di-tertbutyl dicarbonate and potassium carbonate in toluene yielded N-Boc protected amine
derivative 12 in 85% yield (Scheme 4), with spectroscopic data consistent with the data
reported by Corey for the same compound produced as an intermediate in his synthesis.13
Cl

O

Boc2O, K2CO3
NH2

Cl

Toluene, 80°C
85%

Norketamine (2)

O

HN
O

12

O

Scheme 4: Synthesis of tert-butyl (1-(2-chlorophenyl)-2-oxocyclohexyl)carbamate (12)

Preliminary DMSO oxidation studies were performed on compound 12 using either I2 or
N-bromosuccinimide (NBS) as catalysts. Standard reaction conditions reported for this
conversion were optimized for a-methine carbonyl containing substrates and include the
following: ketone (0.5 mmol), NBS or I2 (20 mol %), DMSO (1 mL), at 100 °C, under air
for 24 h.14 When the reaction was performed using either NBS or I2, only norketamine 2
was isolated, suggesting the instability of the N-Boc protecting group under these reaction
conditions. In order to circumvent this problem, a more stable amine protecting group was
selected, namely a methylcarbamate group. Treatment of 2 with methylchloroformate and
sodium carbonate in toluene yielded carbamate 13 in an 84% yield, Reaction of 13 with I2
(20 mol %) in DMSO at 100 °C, under air for as long as 96 hours did not result in
conversion to the oxidized product (only starting material remained), while reaction of 13
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with NBS (20 mol %) in DMSO at 100 °C, under air for 4 days afforded a hydroxylated
product 14 in 37% yield (Scheme 5).
OH
Cl

O

ClCO2CH3; Na2CO3
NH2

Norketamine (2)

Cl

O

Toluene, 80°C
84%

DMSO

O
O

O

NBS

HN

13

Cl

HN
O

37%
14

O

Scheme 5: Synthesis of carbamate 13 and its subsequent DMSO oxidation

The mechanism of DMSO oxidation of ketones catalyzed by iodine or NBS has been
proposed and is believed to operate by way of an initial electrophilic halogenation of the
substrate ketone yielding an α-halogen carbonyl A followed by an SN2 reaction with the
nucleophilic oxygen atom of DMSO yielding an intermediate B/C (Figure V). Protonation
affords the hydroxylation product concomitant with the release of dimethyl sulfide and
regeneration of the halogen catalyst for the next cycle.
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Figure V: Proposed mechanism of NBS or I2 catalyzed DMSO oxidation of ketones14

Due to unforeseen circumstances related to Covid-19, this oxidation reaction was only
performed once. The purified product was analyzed by 1H -NMR, and the data appear
encouraging. But the NMR data is more complex than anticipated, which is suggestive of
a product containing a diastereomeric mixture of 6-hydroxy isomers. Further NMR
analysis needs to be conducted on the product from the reaction.
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Conclusions
A three-step synthesis of norketamine (2) was accomplished in order to produce
starting material for exploring its subsequent I2- or NBS-catalyzed DMSO oxidation.
Although the results of the DMSO oxidation reaction of carbamate protected norketamine
was encouraging, further studies are warranted to optimize reaction conditions and to
confirm both the regiochemistry of hydroxylation, and the relative stereochemistry of the
hydroxylated product. The use of microwave irradiation may be beneficial in the DMSO
oxidation reaction, based on the positive results obtained from the nitration experiments
described using CAN.
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MATERIALS AND METHODS

General Methods:
Commercially available solvents and reagents were purchased from either Sigma
Aldrich Inc., Fisher Scientific, or Alfa Aesar Chemicals. Glassware used for anhydrous
reactions was flame or oven dried and placed under vacuum and purged with argon gas.

Chromatographic Purification:
Thin layer chromatography and UV light source was used to monitor the reaction
progress with references to the starting materials and products using aluminum plates
coated with silica gel and a phosphor. Phosphomolybdic acid was used to stain the TLC
plates when non-UV active compounds were analyzed.
Silica gel column chromatography was performed using 220-440 mesh and
appropriate mobile phase solvents. Fractions were collected and monitored by comparing
sample from test tubes to crude and reference materials using TLC.

Mass Spectrometry:
After TLC confirmed the presence of the desired product, mass spectroscopy data
was obtained to confirm the desired molecular weight of the product. A Waters ZQ single
quadrupole mass spectrometer was employed using an ESI source to monitor MH+ parent
ions or their associated MNa+ adducts.
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NMR Analysis:
NMR spectral data was obtained using a Bruker Ascend™ 400 MHz NMR
spectrometer, and samples were prepared using deuterated chloroform (CDCl3) as the
solvent. Each signal is defined relative to TMS. Proton (1H), carbon (13C), and DEPT-135
NMR spectra were acquired. The TOPSHIM function was utilized to adjust the probe to
the sample. Mestrelab software (MNova) was utilized to analyze raw data. The baseline
correction, peak picking, and integration functions were utilized.

Experimental
2-(2-chlorophenyl)-cyclohexan-1-one (10)
Cesium carbonate (9.10 mg, 27.94 mmol) was added to a 100 mL oven dried round
bottom flask charged with Pd2 (dba)3 (59 mg, 0.064 mmol) and Xantphos (88.6 mg, 0.153
mmol) under a blanket of argon gas. The flask was vacuum purged and refilled with argon
gas three times. Anhydrous 1,4-dioxane (15 mL) was added to the flask, and under argon
gas, freshly redistilled cyclohexanone (9, 2.50 mg, 2.64 mL, 25.48 mmol) and 1-bromo-2chlorobenzene (8, 2.439 g, 1.49 mL, 12.74 mmol) were added. The reaction was heated at
100 °C for 24 hours. In the first 10 minutes of heating, the reaction mixture changed from
a red to a yellow color, and after 25 minutes, it changed to a green color. The final color
was a dark brown. After 24 hours, the sample was cooled to room temperature and then
diluted with diethyl ether (50 mL) and washed with distilled H2O (100 mL). Using a
separation funnel, the organic layer containing the product was extracted with diethyl ether
(3 x 100 mL). The organic layer was washed with brine solution (100 mL), dried over
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MgSO4, filtered using gravity filtration, and concentrated under vacuum. The catalyst
created a sticky product that was slightly water soluble. The product was purified using a
silica gel column and a mobile phase of 10% ethyl acetate/hexanes as an eluent to afford
the purified product of 10 as a white solid (1.4 g, Yield: 51%). 1H NMR (400 MHz,
Chloroform-d) δ 7.40 (dd, J = 7.8, 1.4 Hz, 1H), 7.32 – 7.20 (m, 3H), 4.14 (dd, J = 12.6, 5.4 Hz,
1H), 2.63 – 2.49 (m, 2H), 2.36 – 2.15 (m, 2H), 2.13 – 1.98 (m, 2H), 1.98 – 1.76 (m, 2H). 13C NMR
(101 MHz, CDCl3) δ 208.72, 136.80, 134.21, 129.46, 129.38, 128.13, 126.78, 77.45, 77.14, 76.82,
54.05, 42.39, 33.94, 27.69, 25.69. (ESI) m/z calculated for C12H14ClO (M+H)+ 209.06, found:
209.10 m/z.

2-(2-chlorophenyl)-2-nitrocyclohexan-1-one (11)
For the conventional heating reaction, 2-(2-chlorophenyl)-cyclohexan-1-one (10,
59.3 mg, 0.284 mmol), anhydrous Cu(OAc)2 (99% purity, 11.1 mg, 0.061 mmol), and
(NH4)2Ce(NO3)6 (290 mg, 0.529 mmol) were added into a tube with 1, 2-dichloroethane (4
mL). The reaction mixture was vortexed, then a stir bar was added, the cap was sealed,
and finally, the reaction mixture was stirred in a preheated oil bath at 80°C for 24 hours.
The reaction was monitored by TLC with a mobile phase consisting of 20% ethyl
acetate/hexanes and no product was observed even with prolonging the reaction time for 4
days and also by increasing the reaction temperature to 100°C.
Alternatively, we attempted a microwave irradiation reaction using a 2.45 GHz
Biotage Microwave Initiator employing the same combination of reagents described above.
Microwave radiation was applied to the reaction mixture in 10 minute intervals for 50
minutes at 80°C. Each 10-minute interval was preceded with pre-stirring (2 min). The
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reaction was monitored by TLC with a 20% ethyl acetate/hexanes solvent system. After 50
minutes of the reaction, the reaction mixture was diluted with 30 mL of ethyl acetate, dried
over anhydrous sodium sulfate and the organic portion was filtered one more time,
evaporated under a reduced pressure using a rotary evaporator and the resultant crude
viscous dark yellow residue was purified, using preparative TLC (silica gel, 500-micron
thickness) with 20:80 ethyl acetate/hexanes as an eluent, to afford 16 mg of the desired
product 11 as a pale yellow solid (yield: 22%). 1H NMR (400 MHz, Chloroform-d) δ 7.48 –
7.10 (m, 4H), 3.14 – 2.55 (m, 3H), 2.03 – 1.50 (m, 5H). 13C NMR (101 MHz, CDCl3) δ 199.15,
135.08, 132.04, 131.77, 131.01, 129.04, 127.42, 101.40, 40.62, 36.51, 27.16, 21.92. (ESI) m/z
calculated for C12H12NO3ClNa [M+Na]+ 276.04, found 276.05.

2-(2-chlorophenyl)-2-aminocyclohexan-1-one (norketamine; 2)
Zinc powder (4 x 20 mg; 0.3 mmol; in 30 min intervals) was added to a solution of
2-(2-chlorophenyl)-2-nitrocyclohexan-1-one (13 mg, 0.05 mmol) in AcOH (1.0 mL) under
a blanket of argon. The reaction mixture was stirred for 12 hours and filtered. The filtrate
was concentrated and the residue diluted with dichloromethane and washed with a
saturated aqueous sodium bicarbonate solution (5.0 mL). The aqueous phase was extracted
with dichloromethane (3×4 mL) and the combined organic layers were dried over
anhydrous sodium sulfate, filtered and the solvent was removed under vacuum yield 8 mg
(69%) of product. 1H NMR (400 MHz, Chloroform-d) δ 7.70 (d, J = 7.8 Hz, 1H), 7.41 –
7.30 (m, 2H), 7.30 – 7.22 (m, 1H), 2.81 (d, J = 11.7 Hz, 2H), 2.64 – 2.53 (m, 1H), 2.47
(dd, J = 9.2, 3.9 Hz, 1H), 2.02 (d, J = 6.2 Hz, 1H), 1.89 – 1.59 (m, 3H). 13C NMR (101
MHz, CDCl3) δ 212.46, 139.66, 133.14, 131.07, 129.19, 128.57, 127.29, 77.39, 77.08,
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76.76, 66.62, 41.08, 39.03, 28.54, 22.17. (ESI) m/z calculated for C12H13NO3Cl [M+H]+
224.08, found 224.0.

tert-Butyl (1-(2-chlorophenyl)-2-oxocyclohexyl)carbamate (12)
To a solution of norketamine (2; 100 mg, 0.39 mmol) in toluene (3 mL) was added
potassium carbonate (160 mg, 1.2 mmol) and di-tert-butyl dicarbonate (126 mg, 0.58
mmol). The reaction was heated to 80 °C and stirred for 20 hours. The reaction was cooled,
extracted with ethyl acetate and washed with water. The organic layer dried over anhydrous
sodium sulfate, filtered, and the solvent removed to afford a crude white solid. Purification
by silica gel chromatography (20% ethyl acetate in hexanes) gave 124 mg (Yield: 85%) of
12 as a crystalline white solid. 1H NMR (400 MHz, Chloroform-d) δ 7.87 (d, J = 8.0 Hz,
1H), 7.36 (dt, J = 7.9, 2.0 Hz, 2H), 7.31 – 7.24 (m, 1H), 6.64 (s, 1H), 3.86 (d, J = 14.4 Hz,
1H), 2.50 – 2.26 (m, 2H), 2.07 (td, J = 5.7, 2.7 Hz, 1H), 1.91 – 1.57 (m, 4H), 1.33 (s, 9H).
(ESI) m/z calculated for C17H23ClO3N [M+H]+ 324.14; found, 324.10.

Methyl (1-(2-chlorophenyl)-2-oxocyclohexyl)carbamate (13)
To a mixture of norketamine (2; 100 mg; 0.45 mmol) in anhydrous toluene (3 mL)
and anhydrous Na2CO3 (150 mg), a solution of methyl chloroformate (100 µL) in
anhydrous toluene (300 µL) was added. After heating under reflux for 3 h, the reaction
mixture was cooled to room temperature and washed subsequently with water, 10%
Na2CO3, and water. The product was diluted with ethyl acetate, dried with anhydrous
MgSO4, filtered and concentrated under reduced pressure to yield 106 mg (yield 84%) of
13 as a white solid. 1H NMR (400 MHz, Chloroform-d) δ 7.96 – 6.64 (m, 5H), 3.44 (s,
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3H), 2.48 – 1.43 (m, 8H). 13C NMR (101 MHz, CDCl3) δ 208.87, 154.49, 134.67, 133.88,
131.66, 131.03, 129.54, 126.21, 77.37, 77.05, 76.73, 67.17, 51.63, 39.35, 38.38, 30.80,
22.33. (ESI) m/z calculated for C14H17ClNO3 [M+H]+ 282.08 found, 282.14.

Methyl (1-(2-chlorophenyl)-3-hydroxy-2-oxocyclohexyl)carbamate (14)
Compound 13 (28 mg, 0.1 mmol), iodine crystals (6 mg, 0.02 mmol; 20 mol%),
and DMSO (1 mL) were added to a 5 mL reaction flask fitted with an air-condenser. The
mixture was stirred at 60 °C for 24 hours and monitored by TLC. There was no change in
the reaction even after 3 days and also at higher temperatures of up to 100 °C. After cooling
to room temperature, the solution was diluted with ethyl acetate (10 mL) and washed with
0.1 M Na2S2O3 (5 mL) aqueous solution to quench the unreacted iodine, extracted with
ethyl acetate (3×5 mL), and evaporated under vacuum and unreacted starting material
collected. Substituting iodine crystals for N-bromosuccinimide (5 mg, 0.02 mmol; 20
mol%) and performing the reaction under the same conditions resulted a reaction showing
the formation of a new product by TLC which showed a lower Rf value compared to the
starting material. The reaction was cooled, diluted with ethyl acetate and washed with
water. The organic layer was dried over sodium sulfate, the solvent removed under reduced
pressure to yield a white solid. Purification by silica gel column chromatography (30%
ethyl acetate in hexanes) afforded 11 mg (Yield: 37%) of compound tentatively identified
as 14. 1H NMR (400 MHz, Chloroform-d) δ 7.49 – 7.01 (m, 5H), 5.77 (s, 1H), 4.04 (s, 1H),
3.57 (s, 3H), 2.98 – 1.39 (m, 6H).

23

BIBLIOGRAPHY

1. Belmaker, R.; Agam, G. Major Depressive Disorder. New England Journal of
Medicine 2008, 358 (1), 55–68.
2. Lee, S.; Jeong, J.; Kwak, Y.; Park, S. K. Depression Research: Where Are We
Now? Molecular Brain 2010, 3 (1), 8.
3. FastStats - Depression. https://www.cdc.gov/nchs/fastats/depression.htm (accessed
Mar 23, 2020).
4. Depression. https://www.who.int/news-room/fact-sheets/detail/depression (accessed
Mar 23, 2020).
5. Hillhouse, T. M.; Porter, J. H. A Brief History of the Development of Antidepressant
Drugs: From Monoamines to Glutamate. Experimental and Clinical
Psychopharmacology 2015, 23 (1), 1–21.
6. Sleigh, J.; Harvey, M.; Voss, L.; Denny, B. Ketamine – More Mechanisms of Action
than Just NMDA Blockade. Trends in Anaesthesia and Critical Care 2014, 4 (2-3),
76–81.
7. Zanos, P. NMDAR Inhibition-Independent Antidepressant Actions of Ketamine
Metabolites. European Neuropsychopharmacology 2017, 27.
8. Jose, J.; Dimitrov, I.; Denny, W. Syntheses of Ketamine and Related Analogues: A
Mini Review. Synthesis 2018, 50 (21), 4201–4215
9. Zanos, P.; Highland, J. N.; Stewart, B. W.; Georgiou, P.; Jenne, C. E.; Lovett, J.;
Morris, P. J.; Thomas, C. J.; Moaddel, R.; Zarate, C. A.; Gould, T. D. (2R,6R)Hydroxynorketamine Exerts mGlu2receptor-Dependent Antidepressant
Actions. Proceedings of the National Academy of Sciences 2019, 116 (13), 6441–
6450.
10. Lumsden, E. W.; Troppoli, T. A.; Myers, S. J.; Zanos, P.; Aracava, Y.; Kehr, J.;
Lovett, J.; Kim, S.; Wang, F.-H.; Schmidt, S.; Jenne, C. E.; Yuan, P.; Morris, P. J.;
Thomas, C. J.; Zarate, C. A.; Moaddel, R.; Traynelis, S. F.; Pereira, E. F. R.;
Thompson, S. M.; Albuquerque, E. X.; Gould, T. D. Antidepressant-Relevant
Concentrations of the Ketamine Metabolite (2R,6R)-Hydroxynorketamine Do Not
Block NMDA Receptor Function. Proceedings of the National Academy of
Sciences 2019, 116 (11), 5160–5169.
11. Fukumoto, K.; Fogaça, M. V.; Liu, R.-J.; Duman, C.; Kato, T.; Li, X.-Y.; Duman, R.
S. Activity-Dependent Brain-Derived Neurotrophic Factor Signaling Is Required for
the Antidepressant Actions of (2R,6R)-Hydroxynorketamine. Proceedings of the
National Academy of Sciences 2018, 116 (1), 297–302.
12. Morris, P.J., Moaddel, R., Zanos, P., Moore, C.E., Gould, T., Zarate Jr, C.A. and
Thomas, C.J., 2017. Synthesis and N-methyl-d-aspartate (NMDA) receptor activity
of ketamine metabolites. Organic letters, 19(17), pp.4572-4575.
13. Han Y, Mahender Reddy K, Corey EJ. Simple Enantioselective Syntheses of (2R,
6R)-Hydroxynorketamine and Related Potential Rapid-Onset Antidepressants.
Organic letters. 2017 Oct 6;19(19):5224-7.
14. Liang, Y.F., Wu, K., Song, S., Li, X., Huang, X. and Jiao, N., 2015. I2-or NBScatalyzed highly efficient α-hydroxylation of ketones with dimethyl
sulfoxide. Organic letters, 17(4), pp.876-879.
24

15. Willis, M.C., Taylor, D. and Gillmore, A.T., 2004. Palladium-catalyzed
intramolecular O-arylation of enolates: Application to benzo [b] furan
synthesis. Organic letters, 6(25), pp.4755-4757.
16. Zhang ZQ, Chen T, Zhang FM. Copper-Assisted Direct Nitration of Cyclic Ketones
with Ceric Ammonium Nitrate for the Synthesis of Tertiary α-Nitro-α-substituted
Scaffolds. Organic letters. 2017 Mar 3;19(5):1124-7.

25

SUPPORTING INFORMATION

26

